Contributions
Abstract: PB2023
Type: Publication Only
Background
Hodgkin’s lymphoma (HL) is a highly curable disease. Usually confined to the lymph nodes, extranodal involvement can occur and has an independent prognosis value.
Aims
To analyze the presenting features and the prognostic significance of extranodal disease in HL.
Methods
We performed a retrospective single institution study of 155 HL cases; from January 1992 to December 2010.
The median age was 27 years (range, 15-80 years), Stages III-IV were present in 85 (54.8 %) patients. Combined radio-chemotherapy was administered to 95 (61, 2%) patients and chemotherapy alone to 60 (38.8%).
We analyzed the prognostic relevance of extranodal involvements and their significance was tested according to response rate an overall survival (OS).
Results
Extranodal disease was documented in 52 patients (33.5%) and 49 (44%) had bulky disease. Extranodal sites included the liver in 21 (13.5%), bone marrow in 11 (7%), pleura in 5 (3%), pharynx in 5 (3%), bone in 10 (6%), lung in 4 (1, 7 %) and eye in 1 (0, 6%).
The 52 patients with extranodal disease had poor prognosis compared with the nodal group (5 year OS, 51 % versus 75%; p<0.001). Compared with the nodal subset, the extranodal patients presented more frequently with advanced stage disease (92% vs 08%; p<0.0001), B symptoms (90% vs 10%; p=0.002), a significantly low serum albumin (63.4% vs 24 %; p<0.001) and a higher ESR (77% vs 23% p=0.005).
Complete remission rates in the extranodal and the nodal subsets of patients were 65% vs 84% (p<0.001).
Conclusion
In our study, extranodal disease in patients with HL is frequent, especially in advanced stages, associated with a poor outcome and might be eligible for more effective treatment approach.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): Hodgkin's Lymphoma, prognosis
Abstract: PB2023
Type: Publication Only
Background
Hodgkin’s lymphoma (HL) is a highly curable disease. Usually confined to the lymph nodes, extranodal involvement can occur and has an independent prognosis value.
Aims
To analyze the presenting features and the prognostic significance of extranodal disease in HL.
Methods
We performed a retrospective single institution study of 155 HL cases; from January 1992 to December 2010.
The median age was 27 years (range, 15-80 years), Stages III-IV were present in 85 (54.8 %) patients. Combined radio-chemotherapy was administered to 95 (61, 2%) patients and chemotherapy alone to 60 (38.8%).
We analyzed the prognostic relevance of extranodal involvements and their significance was tested according to response rate an overall survival (OS).
Results
Extranodal disease was documented in 52 patients (33.5%) and 49 (44%) had bulky disease. Extranodal sites included the liver in 21 (13.5%), bone marrow in 11 (7%), pleura in 5 (3%), pharynx in 5 (3%), bone in 10 (6%), lung in 4 (1, 7 %) and eye in 1 (0, 6%).
The 52 patients with extranodal disease had poor prognosis compared with the nodal group (5 year OS, 51 % versus 75%; p<0.001). Compared with the nodal subset, the extranodal patients presented more frequently with advanced stage disease (92% vs 08%; p<0.0001), B symptoms (90% vs 10%; p=0.002), a significantly low serum albumin (63.4% vs 24 %; p<0.001) and a higher ESR (77% vs 23% p=0.005).
Complete remission rates in the extranodal and the nodal subsets of patients were 65% vs 84% (p<0.001).
Conclusion
In our study, extranodal disease in patients with HL is frequent, especially in advanced stages, associated with a poor outcome and might be eligible for more effective treatment approach.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): Hodgkin's Lymphoma, prognosis